Theravance Biopharma confirms zero exposure to Silicon Valley Bank

Theravance Biopharma, Inc.

Company states it holds no cash deposits or securities at Silicon Valley Bank.
Disclosure addresses potential investor concerns about SVB's March 2023 collapse.
No financial impact or operational disruption related to SVB's failure.

item 7.01

Theravance Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-031420

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.